Bristol Myers Squibb Co's (NYSE:BMY) VALOR-HCM Phase 3 study evaluating mavacamten in adults with obstructive hypertrophic cardiomyopathy (obstructive HCM) met its primary endpoint at Week 16.
- The trial included symptomatic obstructive HCM patients who are eligible for septal reduction therapy (SRT).
- The safety of mavacamten was consistent with previous studies.
- "We look forward to sharing the results from VALOR-HCM at the American College of Cardiology 71st Annual Scientific Session & Expo taking place in April," said Roland Chen, M.D., Senior Vice President, Cardiovascular Development at Bristol Myers Squibb.
- Related: Bristol Myers' Mavacamten Added Via $13B Myokardia Buyout, Hit By FDA Delay.
- The 100-subject trial includes three treatment periods: a 16-week placebo-controlled period, a 16-week active treatment period where all patients will receive mavacamten, and a 96-week long-term extension period where all patients will continue to receive mavacamten.
- Obstructive HCM is a chronic, progressive disease in which excessive heart muscle contraction and reduced ability of the left ventricle to fill can make it difficult for blood to circulate.
- Price Action: BMY shares are up 0.26% at $67.95 during the market session on the last check Wednesday.
